Disease Focus Areas

In 2024, Sabin partnered with the Kenya Medical Research Institute (KEMRI) to optimize the use of the oral cholera vaccine.

In recent decades, the incidence of dengue has grown dramatically around the world, with the World Health Organization reporting just over 500,000 global cases in 2000 and more than 5 million in 2019.

A Sabin-hosted public-private movement to prevent Human Papilloma Virus (HPV) infection and eliminate cervical cancer as a public health concern.

We’re developing a vaccine for Marburg, a virus similar to Ebola, and one of the world’s deadliest infectious diseases.

In 2022, there were an estimated 249 million malaria cases worldwide, with the majority occurring in the tropical regions, making this disease a priority area for Sabin.

Measles continues to be a rising threat with concerns surrounding global vaccine hesitancy. In 2023 the WHO released estimates that showed a 20% increase in measles cases over 2022 numbers.

In May 2022, an Mpox outbreak was declared and rapidly spread across Europe, the Americas and then all six WHO regions. Since then, there has also been an upsurge in mpox cases and deaths among several African countries, with additional cases being reported across other countries around the globe.

Since 2019, we’ve been developing a vaccine for Sudan ebolavirus to prevent this deadly virus.

We work to ensure that countries where typhoid is common have the data they need to make strategic decisions about introducing typhoid vaccines. We also partner with scientists and health workers to advance a holistic approach to preventing disease.